ASGR1 and neoplasm: Upon systemic administration, the prepared glycosylated-PEG-oHSV demonstrated highly specific targeting to ASGPR overexpressing tumor cells while sparing the brain, lung, and kidney, which was confirmed by using NIR-II fluorescence imaging and quantified viral replication by qPCR.